Research
-
Trauma Center Hospitals Charged Higher Prices For Some Nontrauma Care Than Non–Trauma Center Hospitals, 2012–18
Abstract Rising prices are a major cause of increased health care spending and health insurance premiums in the US. Hospital prices, specifically—for both inpatient and outpatient care—are the largest driver of rising health care spending in the commercial insurance market. As a result, policy makers and employers are increasingly interested in understanding the determinants of […]
Categorized in -
Medicare Part D Plans Greatly Increased Utilization Restrictions On Prescription Drugs, 2011–20
Part D plans became significantly more restrictive over time, rising from an average of 31.9 percent of compounds restricted in 2011 to 44.4 percent restricted in 2020.
Categorized in -
Testimony on Pharmaceutical Pricing That Balances Innovation and Affordability for Patients with Rare Diseases
Alice Chen delivered testimony to the House Energy & Commerce Health Subcommittee Hearing pm February 29, 2024.
-
A Principled Approach to Non‑Discrimination in Cost‑Effectiveness
Generalized Risk-Adjusted Cost-Effectiveness (GRACE) offers a choice-consistent alternative that admits a premium for disease severity and avoids prohibited discrimination under well-defined conditions on utility and the effects of disability.
Categorized in -
What Drives Poor Quality of Care for Child Diarrhea? Experimental Evidence from India
Provider misperceptions that patients do not want ORS play the biggest role in the underprescribing of ORS.
Categorized in -
Ensuring Affordable and Valuable Pharmaceutical Innovation for Americans
Aligning drug prices with the actual value provided to patients stimulates innovation that benefits patients and discourages innovation that does not. Legislation to increase drug price transparency, coupled with better information about value, can help payers and consumers spend their money wisely.
-
The Evolving Role of Hospitals and Health Systems in Community Health and Emergency Preparedness
Often under financial pressure while being asked to do more, hospitals and health systems need new approaches to ensure high-value care.
Categorized in -
Paying for Advance Care Planning in Medicare: Impacts on Care and Spending Near End of Life
Paying for advance care planning services can be promising in improving patients’ quality of life at end of life (EOL) while lowering EOL spending, especially for patients most vulnerable to receiving aggressive EOL care.
Categorized in -
A Randomized Trial Looking at Planning Prompts to Reduce Opioid Prescribing
The study confirmed the benefit of planning prompts, and repeat letter exposure among clinicians with poor patient outcomes.
Categorized in -
Assessment of the U.S. Food and Drug Administration’s Risk Evaluation and Mitigation Strategy (REMS) for Prasugrel (EFFIENT): A Narrative Review
The prasugrel REMS consisted of passive educational materials whose adequacy was evaluated using highly limited, one-time, cross-sectional surveys. The study’s assessment adds to evidence suggesting the importance of improving the quality and impact of the FDA’s post-approval activities to maximize drug safety.
Categorized in